AKRO Akero Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AKRO

Price (delayed)

$28.12

Market cap

$1.94B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.23

Enterprise value

$1.36B

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, ...

Highlights
AKRO's equity has surged by 176% year-on-year and by 58% since the previous quarter
Akero Therapeutics's quick ratio has increased by 45% YoY and by 3.9% QoQ
AKRO's net income has shrunk by 60% YoY and by 18% QoQ
AKRO's debt is up by 39% year-on-year and by 38% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.akerotx.com
Peers: OMGA ONCT

Key stats

What are the main financial stats of AKRO
Market
Shares outstanding
69.15M
Market cap
$1.94B
Enterprise value
$1.36B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$175.64M
EBITDA
-$175.38M
Free cash flow
-$155.88M
Per share
EPS
-$3.23
Free cash flow per share
-$2.63
Book value per share
$15.03
Revenue per share
$0
TBVPS
$15.38
Balance sheet
Total assets
$912.24M
Total liabilities
$65.99M
Debt
$35.55M
Equity
$846.25M
Working capital
$881.02M
Liquidity
Debt to equity
0.04
Current ratio
30.12
Quick ratio
29.86
Net debt/EBITDA
3.35
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-25.7%
Return on equity
-27.8%
Return on invested capital
-57%
Return on capital employed
-19.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AKRO stock price

How has the Akero Therapeutics stock price performed over time
Intraday
-0.71%
1 week
5.08%
1 month
22.63%
1 year
-32.57%
YTD
20.43%
QTD
19.86%

Financial performance

How have Akero Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$204.07M
Net income
-$179.27M
Gross margin
N/A
Net margin
N/A
Akero Therapeutics's operating income has plunged by 73% YoY and by 18% from the previous quarter
AKRO's net income has shrunk by 60% YoY and by 18% QoQ

Growth

What is Akero Therapeutics's growth rate over time

Valuation

What is Akero Therapeutics stock price valuation
P/E
N/A
P/B
1.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Akero Therapeutics's EPS has decreased by 21% YoY and by 12% QoQ
AKRO's equity has surged by 176% year-on-year and by 58% since the previous quarter
The stock's P/B is 57% below its 5-year quarterly average of 4.3 and 42% below its last 4 quarters average of 3.2

Efficiency

How efficient is Akero Therapeutics business performance
Akero Therapeutics's return on invested capital has surged by 77% YoY
Akero Therapeutics's return on equity has increased by 30% YoY and by 6% QoQ
The ROA has grown by 27% YoY and by 6% from the previous quarter

Dividends

What is AKRO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AKRO.

Financial health

How did Akero Therapeutics financials performed over time
The company's total assets has surged by 162% YoY and by 57% QoQ
The total liabilities has soared by 55% year-on-year and by 47% since the previous quarter
AKRO's debt is 96% smaller than its equity
AKRO's equity has surged by 176% year-on-year and by 58% since the previous quarter
The debt to equity has plunged by 50% YoY and by 20% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.